The European Commission has awarded Boston Scientific a CE Mark for the Vercise primary cell deep brain stimulation system.
The system provides precise neural targeting to address the varying needs of patients suffering from Parkinson's disease, primary and secondary dystonia and essential tremor.
Deep brain stimulation therapy involves the placement of a device that stimulates specific areas in the brain using electrical signals.
The system is not available for use or sale in the United States. — Cynthia Jessup